Format

Send to

Choose Destination
J Control Release. 2015 Sep 28;214:76-84. doi: 10.1016/j.jconrel.2015.07.017. Epub 2015 Jul 17.

Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer.

Author information

1
Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany; Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria.
2
Department of Diagnostic Radiology, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
3
Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
4
CIC biomaGUNE, Molecular Imaging Unit, Paseo Miramón No 182, Parque Tecnológico de San Sebastián, 20009 San Sebastián, Guipúzcoa, Spain.
5
Wilhelimnenspital, Institute of Nuclear Medicine, Montleartstr. 37, 1160 Wien, Austria.
6
Department of Chemistry & Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.
7
Fondazione Filarete, Viale Ortles 22/4, 20139 Milano, Italy.
8
Department of General and Visceral Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany; Department of General-, Visceral-, Transplantation-, Vascular- and Thorax-Surgery LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
9
Institute of Pharmaceutical Technology, Biocenter Niederursel, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany. Electronic address: kreuter@em.uni-frankfurt.de.

Abstract

Highly aggressive cancer types such as pancreatic cancer possess a mortality rate of up to 80% within the first 6months after diagnosis. To reduce this high mortality rate, more sensitive diagnostic tools allowing an early stage medical imaging of even very small tumours are needed. For this purpose, magnetic, biodegradable nanoparticles prepared using recombinant human serum albumin (rHSA) and incorporated iron oxide (maghemite, γ-Fe2O3) nanoparticles were developed. Galectin-1 has been chosen as target receptor as this protein is upregulated in pancreatic cancer and its precursor lesions but not in healthy pancreatic tissue nor in pancreatitis. Tissue plasminogen activator derived peptides (t-PA-ligands), that have a high affinity to galectin-1 have been chosen as target moieties and were covalently attached onto the nanoparticle surface. Improved targeting and imaging properties were shown in mice using single photon emission computed tomography-computer tomography (SPECT-CT), a handheld gamma camera, and magnetic resonance imaging (MRI).

KEYWORDS:

Handheld gamma camera; Maghemite; Magnetic resonance imaging (MRI); Single photon emission computed tomography–computer tomography (SPECT–CT); rHSA nanoparticles; t-PA-ligands to galectins; t-PApeptide1(LAC)

PMID:
26192099
DOI:
10.1016/j.jconrel.2015.07.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center